Title: Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
Authors: Ledermann, Jonathan ×
Harter, Philipp
Gourley, Charlie
Friedlander, Michael
Vergote, Ignace
Rustin, Gordon
Scott, Clare L
Meier, Werner
Shapira-Frommer, Ronnie
Safra, Tamar
Matei, Daniela
Fielding, Anitra
Spencer, Stuart
Dougherty, Brian
Orr, Maria
Hodgson, Darren
Barrett, J Carl
Matulonis, Ursula #
Issue Date: Jul-2014
Publisher: Lancet Pub. Group
Series Title: The Lancet Oncology vol:15 issue:8 pages:852-61
Article number: 10.1016/S1470-2045(14)70228-1
Abstract: Maintenance monotherapy with the PARP inhibitor olaparib significantly prolonged progression-free survival (PFS) versus placebo in patients with platinum-sensitive recurrent serous ovarian cancer. We aimed to explore the hypothesis that olaparib is most likely to benefit patients with a BRCA mutation.
ISSN: 1470-2045
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Gynaecological Oncology
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science